In Depth 27 Jun 2023 The promise of immunotherapy for autoimmune diseases Our immune system serves as the body’s chief line of defense against harmful invaders. But what happens when this mighty defense mechanism turns on its own host, launching an assault on healthy cells and tissues? For the millions of people battling autoimmune diseases, this can severely affect their lives. However, advances in immunotherapy have revolutionized […] June 27, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 5 May 2023Beyond Biotech podcast 44 This week’s podcast is sponsored by Lonza. May is Lupus Awareness Month, and to talk about lupus research with us this week on the podcast are Katherine Tran, senior global market development & marketing manager of the proteomics division at SCIEX, and Allan Stensballe, associate professor, Department of Health Science and Technology and associate professor, […] May 5, 2023 Share WhatsApp Twitter Linkedin Email
More News! 25 Apr 2023 More efficient and cost-effective mRNA vaccines developed A new and patented method for the production of the important mRNA vaccine component pseudouridine is more efficient, sustainable and cost-effective than the previously used chemical synthesis. Researchers from the Institute of Biotechnology and Biochemical Engineering at TU Graz and the Austrian Centre of Industrial Biotechnology (acib) have developed a novel method for the production […] April 25, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 2 Mar 2023 Could new dementia treatment come from intestinal bacteria discovery? Dementia with Lewy bodies (DLB), one of the most common forms of dementia, has no cure. Previous studies suggested that gut bacteria play a role in Parkinson’s disease, another neurodegenerative disorder, but the bacteria involved in dementia with Lewy bodies had not been identified. Now, a group led by researchers at the Nagoya University Graduate […] March 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2022 Watch: Aphaia Pharma interview Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Dec 2022 Enhertu’s positive results demonstrate improvement in overall survival Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […] December 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2022 FDA grants Sensorion Orphan Drug Designation for hearing loss drug Sensorion a clinical-stage biotechnology company has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to OTOF-GT, its lead gene therapy program for hearing loss. The drug is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion is on track to file a clinical trial application (CTA) […] November 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2022 Nutri-tech startup, Novella, grows botanical ingredients without using the plants Nutri-tech start-up Novella, Ltd. will start growing botanical ingredients while leaving the whole plant out of the equation through nutrient cultivation. This original platform in the plant world will help boost global accessibility to high-value nutraceuticals. Addressing the growing demand for botanical micronutrients, the new technology overcomes supply chain disruptions, circumvents climate change, and expands […] November 30, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 28 Nov 2022 Monkeypox stigma and racism set to end by renaming to mpox, WHO reports The World Health Organisation (WHO) said today (November 28) it will begin using mpox, as a synonym for monkeypox. The organization confirmed that both names will be used simultaneously for a year while monkeypox is phased out. This is because of stigmatizing language and monkeypox racism that was appearing online. Some communities observed and reported […] November 28, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 23 Nov 2022 Novo Nordisk announces $750M facility expansion Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […] November 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 18 Nov 2022 Triastek cleared for 3D printed medicine treatment of ulcerative colitis Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […] November 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email